Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion. The offer – which is a 62% premium over Array’s closing share price on Friday – would give Pfizer two already-marketed drugs for melan...
Original Article: As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn